IXT-012

IXT-012 is an investigational drug candidate developed by invoX Pharma for the treatment of idiopathic pulmonary fibrosis (IPF). It is formulated for delivery via the Softhaler® platform, a proprietary dry powder inhalation (DPI) technology acquired through the purchase of Softhale. The Softhaler device is designed to deliver medication effectively to the lungs with low inspiratory effort, which is a significant advantage for patients with compromised respiratory function typical of IPF. As of early 2024, the specific active pharmaceutical ingredient and molecular target for IXT-012 remain undisclosed, but the program is part of invoX's (a subsidiary of Sino Biopharmaceutical) pipeline focused on advancing inhaled therapies for chronic respiratory and systemic diseases.